Evaluation of longterm results of various schemes and modes of palliative hormone therapy in patients with prostate cancer


  • В. М. Григоренко ДУ «Інститут урології НАМН України», м. Київ
  • Р. О. Данилець ДУ «Інститут урології НАМН України», м. Київ
  • С. С. Волков ДУ «Інститут урології НАМН України», м. Київ
  • В. С. Сакало ДУ «Інститут урології НАМН України», м. Київ
  • А. В. Бардін ДУ «Інститут урології НАМН України», м. Київ
  • М. В. Вікарчук ДУ «Інститут урології НАМН України», м. Київ




prostate cancer, palliative hormone therapy, steroidal antiandrogen, a nonsteroidal antiandrogen, an analogue of LHRH, estrogen


Was performed a comparative evaluation of shortand long-term results of treatment under various schemes: a steroid, a non-steroidal anti-androgen in the standard and the reduced dose, LH-RH analogue mode and low-dose estrogen-ADT for patients with prostate cancer stage II–IV. During treatment lowered intensity of complaints, improved urofloumetrichnih indicators, reduction in prostate volume, and a decrease in PSA levels was showed in all groups without significant differences of these parameters between groups. Indicators of general and cancerspecific survival between groups also were not statistically different (p>0,05). The combined use of flutamide in LDEAT mode allows you to achieve a significant therapeutic effect in a short time with less severe side effects, improve patient survival and quality of life. Reduction of the dose flutamide does not reduce the rates of overall and cancerspecific survival and improves the tolerability of treatment.

Author Biographies

В. М. Григоренко, ДУ «Інститут урології НАМН України», м. Київ

V.N. Grigorenko

Р. О. Данилець, ДУ «Інститут урології НАМН України», м. Київ

R.O. Danilets

С. С. Волков, ДУ «Інститут урології НАМН України», м. Київ

S.S. Volkov

В. С. Сакало, ДУ «Інститут урології НАМН України», м. Київ

V.S. Sakalo

А. В. Бардін, ДУ «Інститут урології НАМН України», м. Київ

A.V. Bardin

М. В. Вікарчук, ДУ «Інститут урології НАМН України», м. Київ

M.V. Vikarchuk


United States Cancer Statistics: 1999–2006 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute, 2010.

Oliver SE, May MT, Gunnell D. International trends in prostate-cancer mortality in the ‘PSA-ERA’// Int J Cancer. – 2001. – 92 (6). – P. 893–8.

Helgesen F, Holmberg L, Johansson JE et al. Trends in prostate cancer survival in Sweden, 1960 through 1988, evidence of increasing diagnosis of non-lethal tumours // J Natl Cancer Inst. – 1996. – 88 (17). – P. 1216–21.

Рак в Україні. Бюлетень національного канцер-реєстру України. – К., 2004–2014 рр.

Crawford E.D. Controversies regard- ing screening for prostate cancer / E.D. Crawford, I.M. Thompson // BJU Int. – 2007. – V. 100, Suppl. 2. – P. 5–7.

Huggins C. Studies on prostatic can- cer. I. The effect of castration, of estro- gen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate // Cancer Res. – 1941. – V. 1. – P. 293–297.

Moul JW. Twenty years of controver- sy surrounding combined androgen blockade for advanced prostate cancer // Cancer 2009. – 115 (15). – P. 3376–8.

Hedlund PO, Damber JE, Hager- man I, et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic can- cer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5 // Scand J Urol Nephrol 2008. – 42 (3). – P. 220–9.